

## Saama welcomes Makarand Jawadekar to Board of Advisors

16 January 2018 | News

Dr. Jawadekar brings over three decades of drug discovery and development experience to his partnership with Saama.



Renowned scientist, Makarand Jawadekar, Ph.D. has accepted a position on Saama Technologies, Inc.'s Board of Advisors. Dr. Jawadekar brings over three decades of drug discovery and development experience to his partnership with Saama, including extensive expertise creating and cultivating external alliances to optimize drug discovery as well as drug delivery technologies.

Dr. Jawadekar spent 28 years at Pfizer, where he served as Director of Portfolio Management, as well as Bench Scientist for the formulation of blockbuster drug, Zoloft (sertraline). At Pfizer, Dr. Jawadekar was also responsible for the company's Drug Delivery Technology Assessment function, incorporating external systems into Pfizer's operations. He has extensive experience in clinical trial supply manufacturing, scale-up and technology transfer, performance metrics evaluation and assessment, drug delivery systems assessment, drug product formulation, contracting, outsourcing as well as Pharma R&D performance benchmarking.

Dr. Jawadekar has received numerous distinctions and awards. In 2006, he was invited to serve as part of President George W. Bush's trade delegation to India. He represented Pfizer at the 2009 BioAsia International Conference, and was the recipient of the Indian Pharmaceutical Association's 2001 M.L. Khorana Memorial Lecture of the Year Award.